The FDA approved the PSA test for use in conjunction with a DRE to help detect prostate cancer in men 50 and older, and for monitoring prostate cancer patients after treatment.
FDA同意直肠指(DRE)与PS A测试一起进行,用以帮助检测50岁及以上男性前列腺癌病症,从而在治疗后用以监督前列腺癌患者。
The Prostate Cancer Foundation agrees with the American Urological Association that PSA screening provides important information for men and their doctors.
PSA检查能为病人和他们的医生提供重要信息,在这一点上前列腺癌基金会和美国泌尿协会意见一致。
In one of the first uses of the system, a case manager reviewed 8,076 patients with abnormal PSA test results for prostate cancer, and more than 2,200 patients had follow-up biopsies.
在首次使用该系统的过程中,一位病例管理员查到8,076名病人的前列腺癌PSA检查结果不正常,2,200多名病人随后有做活体组织检查。
应用推荐